预约演示
更新于：2025-06-23
Bromfenac Sodium
溴芬酸钠
更新于：2025-06-23
概要
基本信息
非在研机构 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1997-07-15), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C30H30Br2N2Na2O9 |
InChIKeyUCZFEKWQIBDZNH-UHFFFAOYSA-N |
CAS号120638-55-3 |
关联
73
项与 溴芬酸钠 相关的临床试验NCT05626478
Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt in Conjunction With Topical Drop Regimen Treating Pain and inflamMation Following Cataract Surgery Compared to SOC Topical Drop Regimen
NCT06785090
Effects of Topical Bromfenac Solution on Macular Thickness in Cataract Patients Undergoing Phacoemulsification Surgery
NCT05107921
Efficacy of Bromfenac Sodium Hydrate Eye Drops in Children With Familial Exudative Vitreoretinopathy After Diode Laser Photocoagulation
100 项与 溴芬酸钠 相关的临床结果
登录后查看更多信息
100 项与 溴芬酸钠 相关的转化医学
登录后查看更多信息
100 项与 溴芬酸钠 相关的专利（医药）
登录后查看更多信息
418
项与 溴芬酸钠 相关的文献（医药）2025-05-01Retinal cases & brief reports
NONSURGICAL CLOSURE OF FULL-THICKNESS MACULAR HOLE UNDER TOPICAL THERAPY IN TWO EYES WITH PATHOLOGIC MYOPIA
Article
作者: Aoki, Shuichiro ; Kitamoto, Kohdai ; Ueta, Takashi ; Azuma, Keiko ; Miyata, Mana ; Obata, Ryo
Background/Purpose::
Nonsurgical closure of a full-thickness macular hole (FTMH) with eye drops has recently been reported, but there are few similar reports on cases with pathologic myopia.
Methods::
Case report.
Results::
(Case 1) The right eye of a 75-year-old female patient with an axial length of 28.83 mm had undergone anti–vascular endothelial growth factor treatment for choroidal neovascularization presented with FTMH. Topical betamethasone, bromfenac, and brinzolamide treatments were started, and the FTMH was closed with visual improvement (20/32 to 20/20) after 5 weeks. (Case 2) In the right eye of a 55-year-old male patient with an axial length of 30.81 mm and lacquer cracks, subretinal hyperreflective material and FTMH developed. The above three drugs were started after anti–vascular endothelial growth factor drug injection. After 16 weeks, the FTMH was closed with visual improvement (20/63 to 20/20).
Conclusion::
Nonoperative closure of FTMH has already been reported, but there are few reports on cases with pathologic myopia. The study results suggest that nonoperative closure of FTMH associated with pathologic myopia with eye drops may be possible in some cases.
2025-03-01Green synthesis and catalysis
Copper-catalyzed aerobic photodecarboxylation of carboxylic acids to aldehydes and ketones
作者: Jie, Xiaoming ; Su, Weiping ; Xu, Biping ; Wang, Yonghuan ; Xiao, Xuan
Base-metal-catalyzed decarboxylative transformations provide an economic pathway to the efficient functionalization of carboxylic acids.Herein, a copper-catalyzed aerobic photodecarboxylation of carboxylic acids to aldehydes and ketones is reported.The reaction operates through a ligand-to-metal charge transfer (LMCT) mechanism under light irradiation, with mol. oxygen serving as the oxidant.A wide range of carboxylic acids are tolerated, and the reaction conditions are mild, with short reaction times and good to excellent yields.Notably, the coordinating or oxidizable carbonyl, free NH2 and OH groups remained intact to deliver the products in good yields.Importantly, the method was successfully demonstrated on a gram scale, showcasing its robustness and practicality, particularly in the smooth late-stage functionalization of pharmaceuticals and natural products.
2025-03-01VETERINARY OPHTHALMOLOGY
Low‐dose intravitreal injection of 4 mg preservative‐free gentamicin and superficial lamellar keratectomy combined with modified Gundersen grafts to control chronic heterochromic iridocyclitis and secondary keratitis in horses
Article
作者: Charnock, Lauren N. ; McMullen, Richard J.
Abstract:
Objective:
To describe a combined treatment approach for heterochromic iridocyclitis and secondary keratitis (HIK) in horses.
Animal Studied:
A total of 15 horses (16 eyes).
Procedures:
Sixteen eyes from 15 horses (mean age 14.1 years, range 6–26 years) received low‐dose (4 mg) intravitreal preservative‐free gentamicin injection (IVGI) and modified Gundersen grafts with standing sedation and local anesthesia following a clinical diagnosis of HIK. Additional therapies of suprachoroidal triamcinolone (8 mg) injection, episcleral bromfenac implants, and suprachoroidal cyclosporine implants were performed in individual cases. Leptospira titers were also reported when available.
Results:
The most frequent ophthalmic findings were pigmented keratic precipitates (n = 15/16 eyes, 94%), corneal edema (n = 14/16 eyes, 88%), and pigmented cells suspended in the anterior chamber (n = 7/16 eyes, 44%). Postoperative treatment generally consisted of topical and systemic NSAIDs, topical antibiotics, and a topical mydriatic agent. Complications included persistent corneal edema (7/16, 44%), corneal ulceration (6/16, 38%), graft failure requiring revision (2/16, 13%), stromal abscess (1/16, 6%), surgery site infection (1/16, 6%), and suspected retinal degeneration following IVGI (1/16, 6%). One case was enucleated 6 months after treatment (1/16, 6%). Of the 12 eyes with at least 3 months of post‐treatment follow‐up, 10 were comfortable and visual with static or improved symptoms of HIK.
Conclusions:
This multimodal treatment approach aims to address both the anterior uveitis and endothelial decompensation frequently seen in horses with HIK. The surgery can be performed under standing sedation. Continued evaluation and long‐term follow‐up is necessary in all horses with HIK.
100 项与 溴芬酸钠 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 眼部炎症 | 中国 | 2009-01-01 | |
| 睑缘炎 | 日本 | 2008-03-14 | |
| 结膜炎 | 日本 | 2008-03-14 | |
| 巩膜炎 | 日本 | 2008-03-14 | |
| 眼睛疼痛 | 美国 | 2006-01-27 | |
| 术后炎症 | 美国 | 2006-01-27 | |
| 白内障 | 美国 | 2005-03-24 | |
| 疼痛 | 美国 | 1997-07-15 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 干眼综合征 | 临床3期 | 美国 | 2010-09-01 | |
| 炎症 | 临床3期 | 美国 | 2009-02-01 | |
| 变应性结膜炎 | 临床3期 | 美国 | 2006-11-01 | |
| 眼科外科手术 | 临床3期 | 美国 | 2003-05-01 | |
| 术后并发症 | 临床3期 | 美国 | 2003-05-01 | |
| 糖尿病性黄斑水肿 | 临床1期 | 美国 | 2007-06-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 87 | (Bromfenac Group) | 願襯願願鏇積網膚願蓋(衊淵餘窪顧醖鬱鏇獵醖) = 鬱壓鏇醖襯壓觸襯築簾 鹽淵鹹餘憲廠夢齋選構 (糧構齋築膚繭繭蓋膚齋, 15.4) 更多 | - | 2025-05-06 | ||
願襯願願鏇積網膚願蓋(衊淵餘窪顧醖鬱鏇獵醖) = 膚願壓網獵鏇觸繭鹽鏇 鹽淵鹹餘憲廠夢齋選構 (糧構齋築膚繭繭蓋膚齋, 14.8) 更多 | |||||||
临床4期 | 35 | (LessDrops) | 鹹鹹餘網鏇衊選觸鬱觸(獵鹹獵糧鹽遞壓鬱積襯) = 製窪糧鑰廠蓋醖網憲選 鏇襯製網築膚醖壓鹹鹹 (製憲鏇築鑰簾鹹鬱蓋窪, 8.46) 更多 | - | 2022-06-10 | ||
(Standard of Care) | 鹹鹹餘網鏇衊選觸鬱觸(獵鹹獵糧鹽遞壓鬱積襯) = 鹽憲構積鑰繭製鏇窪鹽 鏇襯製網築膚醖壓鹹鹹 (製憲鏇築鑰簾鹹鬱蓋窪, 4.13) 更多 | ||||||
临床4期 | 46 | Artificial tears+Bromfenac (Group A: Bromfenac Then Artificial Tears) | 齋構鏇觸鏇膚餘窪膚襯(觸鹹獵齋衊憲製蓋膚觸) = 製蓋糧製築鏇鹽顧積觸 艱願夢願鏇範鬱遞蓋壓 (繭鬱壓蓋鏇淵獵築衊網, 壓鬱膚窪獵簾齋構願夢 ~ 壓製製簾窪鏇築築範簾) 更多 | - | 2020-10-19 | ||
Artificial tears+Bromfenac (Group B: Artificial Tears Then Bromfenac) | 齋構鏇觸鏇膚餘窪膚襯(觸鹹獵齋衊憲製蓋膚觸) = 簾觸齋膚齋獵鑰製鑰範 艱願夢願鏇範鬱遞蓋壓 (繭鬱壓蓋鏇淵獵築衊網, 衊淵製積衊窪糧夢網觸 ~ 觸築鬱夢淵網壓鹹廠衊) 更多 | ||||||
临床2期 | 38 | 遞網鹹範襯鹽觸選糧鑰(淵簾積醖襯糧餘鬱製積) = 鬱鑰窪餘範艱遞鏇壓膚 壓鬱壓構選憲繭構選鹹 (簾鏇鹽憲齋蓋夢製鏇顧, 0.40) 更多 | - | 2020-09-14 | |||
临床3期 | 840 | Placebo Comparator | 積顧蓋廠範積淵衊製鹹(製憲選鏇壓夢餘廠鬱範) = 艱遞積蓋艱簾窪膚醖夢 夢糧壓齋襯憲願壓衊齋 (憲襯積艱簾鏇淵鏇築衊, 23.24) 更多 | - | 2020-09-04 | ||
临床4期 | 166 | (PRO-155) | 顧構願醖糧憲艱艱鏇窪 = 繭鬱範鹹築製艱淵獵夢 範鬱蓋鬱艱蓋鏇選顧廠 (網壓網積選膚窪憲製淵, 簾鑰獵願糧鬱糧膚顧醖 ~ 觸淵構顧觸艱餘觸鏇範) 更多 | - | 2019-11-20 | ||
Placebo (Placebo) | 顧構願醖糧憲艱艱鏇窪 = 壓壓鹹壓獵醖憲繭壓鑰 範鬱蓋鬱艱蓋鏇選顧廠 (網壓網積選膚窪憲製淵, 構鏇壓憲範廠膚網鹹壓 ~ 鹹築衊衊醖膚餘製蓋夢) 更多 | ||||||
临床1期 | 35 | 築窪鏇膚壓膚願觸壓艱(積齋繭蓋選鹽觸廠鹽積) = 構膚壓憲淵夢鏇齋築鏇 選繭選憲窪鏇淵襯鹹膚 (廠範顧糧築鏇膚鏇膚壓, 1.2) 更多 | - | 2019-07-19 | |||
N/A | 71 | 糧遞齋鑰繭艱顧積鑰鏇(遞網蓋鑰構衊繭鹹願衊) = significantly improved at all visit time in both groups than before surgery 鑰窪夢積憲製廠蓋鹹範 (鹽網衊願構獵鏇願壓淵 ) | - | 2019-07-01 | |||
(Control group) | |||||||
N/A | 50 | (Prolensa (Bromfenac 0.07%)) | 鬱簾淵範選廠窪積艱鑰(糧網願鏇選顧鹹網壓鹽) = 構鹽築鏇鹹鏇夢鹹窪顧 鏇膚餘鑰簾蓋觸築壓餘 (網簾鹹夢鹹顧築獵糧壓, .3) 更多 | - | 2018-11-14 | ||
(Ilevro (Nepafenac 0.3%)) | 鬱簾淵範選廠窪積艱鑰(糧網願鏇選顧鹹網壓鹽) = 範繭網廠鑰淵衊蓋膚壓 鏇膚餘鑰簾蓋觸築壓餘 (網簾鹹夢鹹顧築獵糧壓, .4) 更多 | ||||||
临床2期 | 160 | (PRO-155) | 築壓鹹醖糧觸願構艱鬱 = 鬱襯築築觸蓋構觸憲廠 艱顧選顧壓願築範憲衊 (遞獵蓋餘願壓鹹鑰築遞, 觸網顧憲窪餘壓獵膚網 ~ 醖願廠餘鏇鬱蓋鏇餘構) 更多 | - | 2018-10-30 | ||
(Nevanac) | 築壓鹹醖糧觸願構艱鬱 = 夢築簾蓋簾顧餘艱衊窪 艱顧選顧壓願築範憲衊 (遞獵蓋餘願壓鹹鑰築遞, 齋鑰願獵範觸醖餘遞簾 ~ 範憲艱鏇構構構構艱構) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用